Oxford Genetics Secures GBP1 Million Investment for Gene Therapy Technologies

November 1, 2016

Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.

Synthetic biology company, Oxford Genetics announced that it has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies. Mercia Technologies is making the investment as part of its focus on supporting the creation, funding, and scaling of innovative technology businesses with growth potential. 

Oxford Genetics recently relocated to new, state-of-the-art facilities in Oxford Science Park. The move gives the team access to dedicated cell development suites and new technology capable of automating certain processes, allowing the company to scale its services in line with increasing customer demand, and reinforce its position in DNA design, protein expression, and virus and cell line engineering.

Oxford Genetics first received investment from Mercia Technologies in July 2015, who now holds a 46% share in the company and this latest round of funding will enable Oxford Genetics to continue licensing its technologies within the rapidly expanding markets of cell and gene therapy.